Home › Research › Tau biomarkers
CSF-tau and CSF-Abeta(1-42) in posterior cortical atrophy
Thomas P Baumann, Hüseyin Duyar, Marc Sollberger, Jens Kuhle, Axel Regeniter, Baltazar Gomez-Mancilla, Klaus Schmidtke, Andreas U Monsch. Dementia and geriatric cognitive disorders, 2010-07-01
Topic: Plasma and spinal-fluid biomarkers
Plain-language summary
The Abeta(1-42), T-tau and P-tau(181) levels in PCA patients differed significantly (p < 0.02) from those in healthy controls but were indistinguishable from subjects with a clinical diagnosis of AD. High T-tau and P-tau(181) and low Abeta(1-42) levels in PCA - typically observed in AD - indicate that the underlying pathology of PCA is usually AD. If these findings are replicated in PCA patients with autopsy-confirmed AD neuropathology, PCA patients may be eligible for disease-modifying AD treatments.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Baumann, T. P., Duyar, H., Sollberger, M., Kuhle, J., Regeniter, A., Gomez-Mancilla, B., et al. (2010). CSF-tau and CSF-Abeta(1-42) in posterior cortical atrophy. Dementia and geriatric cognitive disorders. https://doi.org/10.1159/000314679
Vancouver
Baumann TP, Duyar H, Sollberger M, Kuhle J, Regeniter A, Gomez-Mancilla B, et al. CSF-tau and CSF-Abeta(1-42) in posterior cortical atrophy. Dementia and geriatric cognitive disorders. 2010. doi:10.1159/000314679. PMID: 20606434.
BibTeX
@article{baumann2010-20606434,
author = {Baumann, Thomas P and Duyar, Hüseyin and Sollberger, Marc and Kuhle, Jens and Regeniter, Axel and Gomez-Mancilla, Baltazar and Schmidtke, Klaus and Monsch, Andreas U},
title = {{CSF-tau and CSF-Abeta(1-42) in posterior cortical atrophy}},
journal = {Dementia and geriatric cognitive disorders},
year = {2010},
doi = {10.1159/000314679},
pmid = {20606434},
url = {https://doi.org/10.1159/000314679}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- The Abeta(1-42), T-tau and P-tau(181) levels in PCA patients differed significantly (p < 0.02) from those in healthy controls but were indistinguishable from subjects with a clinical diagnosis of AD.
- High T-tau and P-tau(181) and low Abeta(1-42) levels in PCA - typically observed in AD - indicate that the underlying pathology of PCA is usually AD.
- If these findings are replicated in PCA patients with autopsy-confirmed AD neuropathology, PCA patients may be eligible for disease-modifying AD treatments.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants34
- Evidence strengthLow
How this study scored 45/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 25 of the 56 points we could judge it on, which is 45 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Dementia and geriatric cognitive disorders) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2010 — within 20 year(s) of the newest study here |
| Sample size | 1 / 4 | 34 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 20606434) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 25 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 25 of the 56 points we could judge it on is 45 out of 100. |
| Total | 45 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Tau biomarkers from nearby years
Also in Tau biomarkers
61 studies in the library are filed under Tau biomarkers with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Tau biomarkers hub.